James Whitlock, MD
Co-Chair
Dr. James Whitlock is the Head of the Division of Haematology/Oncology at The Hospital for Sick Children.
His research interests include the biology and treatment of childhood acute leukemias, the development of new drugs for the treatment of childhood cancers, and the biology and treatment of histiocytic disorders.
James was the inaugural Vice-Chair for New Agents and Relapse studies for the Acute Lymphoblastic Leukemia Committee of the Children’s Oncology Group (COG). He is the lead investigator for an international phase I trial of nelarabine combination therapy for relapsed T-cell ALL (T2008-002: NECTAR) through Therapeutic Advances in Childhood Leukemia (TACL) consortium and served two terms as the first chair of TACL’s Steering & Prioritization Committee.
He is a past President of the Histiocyte Society, an international scientific organization which supports research in, and conducts clinical trials for, histiocytic disorders. He is the current Chair of C17, the national organization for Canadian childhood cancer and blood disorder centres.